<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Taba">
 <table frame="hsides" rules="groups">
  <tbody>
   <tr>
    <td align="left">In the PIX301 study, patients with relapsed/refractory non-Hodgkin lymphoma who achieved a complete response with pixantrone had various responses to prior therapies (complete or partial response, stable or progressive disease).</td>
   </tr>
   <tr>
    <td align="left">Four patients receiving pixantrone who had previously had a complete or partial response (
     <italic>n</italic> = 1 each) or progressive disease (
     <italic>n</italic> = 2) with prior therapies, were free from progression for more than 400 days.
    </td>
   </tr>
   <tr>
    <td align="left">These results suggest that pixantrone monotherapy can induce durable responses and long-term remission in some patients with relapsed/refractory non-Hodgkin lymphoma. These responses appear unrelated to the response to prior therapies.</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
